• Explore /
  • Poster
  • / Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN.

Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN.

Abstract Video & Slides Poster

Authors

null

Jeff Porter Sharman

Willamette Valley Cancer Institute and US Oncology Research Center, Eugene, OR

Jeff Porter Sharman , Miklos Egyed , Wojciech Jurczak , Alan P. Skarbnik , Manali K. Kamdar , Talha Munir , Laura Fogliatto , Yair Herishanu , Versha Banerji , George Follows , Patricia Walker , Karin Karlsson , Paolo Ghia , Ann Janssens , Emmanuelle Ferrant , Veerendra Munugalavadla , Ting Yu , Min Hui Wang , Jennifer Ann Woyach

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Chronic Lymphocytic Leukemia (CLL) and Hairy Cell

Clinical Trial Registration Number

NCT02475681

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7539)

DOI

10.1200/JCO.2022.40.16_suppl.7539

Abstract #

7539

Poster Bd #

192

Abstract Disclosures

Similar Posters

First Author: Jeff Porter Sharman

First Author: Wojciech Jurczak

First Author: Othman Al-Sawaf

First Author: Myuran Thana